Pediatric Migraine Study

Ten percent of school age children have migraine, and it can be associated with significant functional disability, such as missing school, sports, social and family time.  Girls and boys have about the same incidence of migraine until puberty, when it increases in girls and remains stable or decreases in boys.  Non-pharmacologic tenants of good migraine management include adequate sleep, proper hydration, exercise, health foods, and learning how to manage stress. Non-pharmacologic interventions at our center include education in diet, sleep hygiene, exercise and stress management, biofeedback, cognitive-behavioral therapy, physical therapy and massage.

Some migraines, however, simply require medicines.  While over-the-counter analgesics like Ibuprofen may help a low-level headache, true migraine often needs better, more specific therapy.  While we have a number of good options for adults, there are not that many migraine-specific treatment choices for children and adolescents.  Our pediatric migraine research program aims to change that, and bring safe, effective and well-tolerated pediatric migraine treatments to the market.  Our current and upcoming studies include:

  •  We currently are offering a study for children and adolescents who have migraines. This study is looking to see if an already approved FDA medication currently being used for adults, will help treat and prevent migraines in children and adolescents as well. This study is looking at children who have either episodic or chronic migraines. For those who qualify, the study begins with a double-blind phase. After this 24-week period, the patient can then roll over to an open label phase where they would receive the study medication for up to 40 weeks. Click the button to view information about this study on clinicaltrials.gov. Learn more (Chronic) / Learn More (Episodic)
  • This is one of our migraine studies for pediatric and adolescent patients. This study is looking at a medication that has already been approved by the FDA for the prevention of migraines in adults. The study is looking at how the medication is absorbed and how well it works in children and adolescents. This study is an open label study, meaning that patients who qualify will receive the study medication right from the start. Click the button to view information about this study on clinicaltrials.gov. Learn more 
  • This is a nice and quick study for our pediatric (over 6 but under 12 years old) patients. This is a single dose study for a medication used to treat and stop a migraine. The medication has been already approved by the FDA for use in adults and this study is to see if the medication will work for children as well, and to gather data to see how the medication is processed by the younger body. Please feel free to give us a call at (203) 914-1903 or email us at info@neicr.com for more information.
          

  • This study is for a medication (already approved for treatment in adults) to treat and stop a migraine in children and adolescents. The study is looking for children 6 and older, but not older than 18 to participate. The patients in this study have a chance of getting either a placebo (a sugar pill) or the active medication. The entire study can take up to 19 weeks with a total of 4 visits to the clinic. Click the button to view more information about this study on clinicaltrials.gov. Learn More

  • We have a two-part study for some of our pediatric patients with migraine. This study begins with a single dose blinded phase where your child will treat a single migraine with a dose of medication. After this, your child will come back to our office and have the potential to roll over into an open label study that can last up to a year. This medication has already been approved for the treatment of migraine in adults. Click the button to view more information about this study on clinicaltrials.gov. Learn More (Initial Study) / Learn More (Extension)

  • This study is for our younger migraine sufferers, aged 6 to 11. This medication is a preventative medication for migraines in the form of a daily oral pill. The FDA has already approved it for use in adults and adolescents aged 12-18. The time commitment for our patients is about 1-2 hours a month for a period of 6 months. Click the button to view more information about this study on clinicaltrials.gov. Learn More

 

All studies at NEICR are available at no cost to you, and there may be compensation for time and travel.  Participation is completely voluntary, and you may withdraw at any time. To find out more about any of our studies, give us a call at 203-914-1903 or fill out the form below.

Use the form below to let us know you are interested:

Pediatric Migraine - Clinical Study Enrollment
First
Last
Sending